PIK3CG and melanoma: To assess the precise contribution of PI3K/AKT activity in BRAF/MEK inhibitor resistance, we selected gain-of-function PIK3CAH1047R and AKT3E17K mutations, both identified in melanoma and associated with BRAF inhibitor resistance2.